Europe’s Medical Cannabis at a Digital Crossroads: Access, Regulation, and the Future of Telemedicine

Online consultations, e-prescriptions, mail-order pharmacies: For many cannabis patients, medical care in Europe has become easily accessible for the first time. In Germany, in particular, the combination of the Cannabis Act, destigmatization, and digital access has massively accelerated the market. But this very success is now attracting political attention.

What began as modern healthcare is suddenly under suspicion: too easy, too fast, and with insufficient oversight.This conflict will be a prominent topic at Cannabis Europa London 2026, taking place on May 26th and 27th, 2026 at the Barbican Centre.

The conference describes itself as a meeting point for politics, capital, and the legal cannabis industry—and in 2026, the question will be whether Europe’s medical cannabis market continues to grow digitally or will be hampered again by political measures.A central theme is: “The End of E-Prescriptions? Europe’s Telehealth Crossroads .” The title itself reveals the topic.

Telemedicine has accelerated the supply of cannabis in Europe, but regulators in Germany and other countries want to further restrict online prescriptions and mail-order sales. The Cannabis Industry Council explicitly points out that Germany and other markets are cracking down on online prescribing and mail-order sales, while Poland has already adopted a more restrictive approach.

Germany is at the center of the debate

Germany is the key market in this debate. Since medical cannabis is no longer subject to narcotics legislation, access has become easier. At the same time, the number of digital platforms has grown, connecting patients with doctors and pharmacies via online questionnaires, video consultations, or digital medical histories. For many patients, this has meant shorter waiting times, less stigma, and better availability.But the Federal Ministry of Health wants to counteract this.

A draft amendment to the Medicinal Cannabis Act stipulates that cannabis flowers can only be prescribed after a personal doctor-patient consultation. Furthermore, mail-order sales of cannabis flowers are to be restricted or prohibited. Legal analyses by Hogan Lovells and Taylor Wessing describe these planned changes as a significant tightening of regulations compared to the current digital access.

The rationale is well-known: prevent abuse, stop bogus consultations, ensure medical quality. That sounds reasonable. But the political question is whether telemedicine needs to be rolled back across the board—or whether it could be better regulated. Because the difference between dubious mass prescribing and genuine digital care lies not in the screen, but in standards: medical responsibility, comprehensible documentation, secure identity verification, laboratory quality, pharmacy control, and transparent dosage.

Poland shows what can happen

The situation in Poland is particularly instructive. There, telemedicine access to medicinal cannabis was severely restricted in November 2024. According to Business of Cannabis, prescriptions fell by 54 percent within two months of the restrictions . At the same time, the market later recovered: by December 2025, volumes had even exceeded pre-slump levels.This is the crucial point: Demand doesn’t disappear just because digital access is made more difficult. Patients continue to seek care. Providers adapt. Markets shift. Some return to traditional practices, others opt for less transparent pathways.

Poland thus demonstrates not only that regulation works—but also that drastic measures often initially create gaps in care.Prohibition Partners describes the Polish case as a particularly data-rich example of what happens when a market relies heavily on telemedicine and is then suddenly slowed down by regulation: Sales volumes halve in a short time, but the market later stabilizes again.

Europe’s cannabis question is also a question of digitalization

Medical cannabis is merely the most visible conflict here. The real issue is a larger one: Does digital medicine still apply when the prescribed medication is politically sensitive? Or will cannabis once again be treated as a special commodity, where mistrust is more important than access to care?Especially for people with chronic illnesses, pain patients, sleep disorders, neurological conditions, or mental health challenges, digital access can be crucial.

Not every patient lives in a large city with doctors who prescribe cannabis. Not every practice is knowledgeable about it. Not everyone wants to explain in the waiting room why they need cannabis as medicine.Telemedicine can fill this gap. But it can also be misused. That’s precisely why smart regulation is needed—not a return to care provided by chance.
The mistake would be the wrong brake.

Of course, the market needs regulation. No one benefits if medical cannabis becomes a mere order-only commodity requiring a prescription. But a blanket attack on online prescriptions and mail-order pharmacies doesn’t just affect problematic providers. It also hurts patients who have finally found reliable access.The real task, therefore, is not to stifle telemedicine for cannabis.

The task is to mature it. This includes clear requirements for medical consultations, mandatory documentation, plausibility checks, age and identity verification, transparent product information, pharmacy standards, and consistent action against providers who use medicine merely as a sales gimmick.Europe is at a crossroads. Will medicinal cannabis be treated like a modern drug that can be prescribed and dispensed digitally? Or will cannabis remain a special case where old prejudices overshadow any innovation?

Commentary Conclusion

Digital access to cannabis isn’t the problem. The problem is a market that has grown faster than the political capacity to regulate it properly. Germany should learn from Poland: Abruptly restricting access doesn’t automatically reduce demand; it merely shifts it.Instead of restricting prescriptions, Europe needs a quality initiative. Good telemedicine is not a loophole. It is part of modern healthcare—including for cannabis.

__

(Featured image by GRAS GRUN via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in HanfJournal. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.